# Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer

> **NCT01374087** · PHASE2 · TERMINATED · sponsor: **Ipsen** · enrollment: 32 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Triptorelin 22.5 mg
- **RADIATION:** Brachytherapy

## Key facts

- **NCT ID:** NCT01374087
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-11
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Slow enrollment of patients.
- **Last updated:** 2019-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01374087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01374087, "Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01374087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*